title: Effect of postoperative steroids on the refractive outcome of photorefractive keratectomy for myopia with the Summit excimer laser.
abstract: To assess the role of topical steroids following excimer laser photorefractive keratectomy (PRK) for myopia, we compared the refractive outcome in 100 eyes that did not receive steroids in the immediate postoperative period (untreated eyes) with 100 eyes that were treated with topical dexamethasone for three months postoperatively. Photorefractive keratectomy was performed with the Summit laser, using 4.3 mm and 4.5 mm ablation zones. At three months after surgery, the untreated eyes had a mean refraction of -0.97 +/- 1.15 diopters (D), significantly different (P < .01) from the mean refraction (+0.46 +/- 0.74 D) of the steroid-treated eyes. By six months postoperatively, 86% of the untreated eyes had regressed to a myopia of at least 0.50 D, whereas only 23% of the steroid-treated eyes had regressed. In a second study, we compared the results in 25 patients whose first PRK eye was treated with steroids after surgery but whose second eye was not. At three months postoperatively, mean refraction in the steroid-treated eyes was +1.23 +/- 0.71 D, significantly different (P < .01) from the mean of -0.45 +/- 1.29 D in the untreated eyes. The refractive results in PRK eyes treated with the Summit unit and with relatively small ablation zone diameters showed that eyes that received dexamethasone postoperatively were less likely to regress to myopia.
authors.affiliation: St. Erik's Eye Hospital (Karolinska Institutet), Stockholm, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Fagerholm
authors.forename: H
authors.initials: H
authors.lastname: Hamberg-Nyström
authors.forename: B
authors.initials: B
authors.lastname: Tengroth
authors.forename: D
authors.initials: D
authors.lastname: Epstein
mesh_terms: D000287:Administration, Topical; D000328:Adult; D003315:Cornea / Q000187:drug effects / Q000601:surgery*; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053685:Laser Therapy; D008297:Male; D009216:Myopia / Q000601:surgery*; D009883:Ophthalmic Solutions; D011182:Postoperative Care; D011446:Prospective Studies; D012029:Refraction, Ocular; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D009883:Ophthalmic Solutions; D003907:Dexamethasone